Earnings

MDT reported earnings of $977 million, or 98 cents per share, up from $762 million, or 75 cents per share, a year ago. Adjusted EPS was $1.01 – above analysts’ estimate of 97 cents.

Revenue
Revenue increased to $4.318 billion from $4.163 billion last year. Analysts expected to see revenue of $4.25 billion.

At the end of January, Medtronic closed its $43 billion merger deal with Ireland-based Covidien. The deal will allow the company to re-incorporate in Ireland and will also provide the company with much needed diversification. This new diversification will partially offset the loss of market share in some of its businesses.

Investors interested in MDT may be interested in the funds listed below. These funds currently have the largest stakes in the company.

The funds listed above allow investors to gain exposure to MDT while remaining diversified. Investors interested in MDT may also be interested in St. Jude Medical (STJ) and Boston Scientific (BSX).